Sarah R Poll, Flavia M Facio, Kirsty McWalter, Patricia C Lopes, Amanda Lindy, Bethany Friedman, Kirsten Kelly, Olivia Trimmier, Jane Juusola, Paul Kruszka, Wei Wang, Lisa Dyer, Lisong Shi, Britt Johnson, Ganka Douglas
ES/GS matched or exceeded CMA performance for CNV detection and identified additional variant types. These findings support the adoption of ES/GS as first-tier tests for CNV detection, streamlining diagnostic workflows, and improving diagnostic rate by capturing both small and large structural variants with high accuracy.
PURPOSE: Copy number variants (CNVs) are implicated in many health conditions. Chromosomal microarray (CMA) has traditionally been the first-tier test for CNV detection. However, exome and genome sequencing (ES/GS) can identify CNVs alongside other variant types. This study compared CNV detection using CMA versus ES/GS in a large clinical cohort.
METHODS: CNV calls from CMA and ES/GS were analyzed in a diverse cohort of over 9,000 individuals tested in a high-throughput clinical laboratory. Concordance between platforms was evaluated, with discordant findings reviewed to determine their nature and causes.
RESULTS: ES/GS showed >99% concordance with CMA. CMA results not detected on ES/GS were typically CNV <3 exons, CNV outside regions of interest, or low-level mosaicism. Interestingly, 0.68% of cases had a CNV reported by ES/GS only, usually CNVs below the CMA detection limit. The additional CNV detection of CMA after ES/GS was ≤1%. When considering non-CNV findings, the added yield of ES/GS was >41%.
CONCLUSION: ES/GS matched or exceeded CMA performance for CNV detection and identified additional variant types. These findings support the adoption of ES/GS as first-tier tests for CNV detection, streamlining diagnostic workflows, and improving diagnostic rate by capturing both small and large structural variants with high accuracy.